CYP17 polymorphisms and prostate cancer outcomes

Prostate

Volumn 70, Issue 10, 2010, Pages 1094-1101

  Wright, Jonathan L ^a,b   Kwon, Erika M ^c   Lin, Daniel W ^a,b   Kolb, Suzanne ^b   Koopmeiners, Joseph S ^b   Feng, Ziding ^b   Ostrander, Elaine A ^c   Stanford, Janet L ^b,d  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

CYP17; Population based; Prostate cancer; Single nucleotide polymorphisms; Survival

Indexed keywords

ABIRATERONE ACETATE; CYTOCHROME P450 17; DNA; KETOCONAZOLE; STEROID 17ALPHA MONOOXYGENASE;

ADULT; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; CYP 17 GENE; FOLLOW UP; GENE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN FUNCTION; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES; WATCHFUL WAITING; CANCER REGISTRY; CASE CONTROL STUDY; CHEMISTRY; DISEASE COURSE; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENETICS; MIDDLE AGED; MORTALITY; POLYMERASE CHAIN REACTION; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; TUMOR RECURRENCE;

ADULT; CASE-CONTROL STUDIES; COHORT STUDIES; DISEASE PROGRESSION; DNA, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; SEER PROGRAM; STEROID 17-ALPHA-HYDROXYLASE; WASHINGTON;

EID: 77953392982     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21143     Document Type: Article

References (31)

1. Picado-Leonard J, Miller WL. Cloning and sequence of the human gene for P450c17 (steroid 17alpha-hydroxylase/17,20 lyase): Similarity with the gene for P450c21. DNA1987;6(5):439-448.
2. Yamada Y, Watanabe M, Murata M, Yamanaka M, Kubota Y, Ito H, Katoh T, Kawamura J, Yatani R, Shiraishi T. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population. Int J Cancer 2001;92(5):683-686.
3. Kittles RA, Panguluri RK, Chen W, Massac A, Ahaghotu C, Jackson A, Ukoli F, Adams-Campbell L, Isaacs W, Dunston GM. Cyp17 promoter variant associated with prostate cancer aggressiveness in African Americans. Cancer Epidemiol Biomarkers Prev 2001;10(9):943-947. (Pubitemid 32844901)
4. Lunn RM, Bell DA, Mohler JL, Taylor JA. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 1999;20(9):1727-1731.
5. Gsur A, Bernhofer G, Hinteregger S, Haidinger G, Schatzl G, Madersbacher S, Marberger M, Vutuc C, Micksche M. A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int J Cancer 2000;87(3):434-437.
6. Stanford JL, Noonan EA, Iwasaki L, Kolb S, Chadwick RB, Feng Z, Ostrander EA. Apolymorphismin the CYP17 gene and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2002;11(3): 243-247. (Pubitemid 34327000)
7. Wadelius M, Andersson AO, Johansson JE, Wadelius C, Rane E. Prostate cancer associated with CYP17 genotype. Pharmacogenetics 1999;9(5):635-639.
8. Habuchi T, Liqing Z, Suzuki T, Sasaki R, Tsuchiya N, Tachiki H, Shimoda N, Satoh S, Sato K, Kakehi Y, Kamoto T, Ogawa O, Kato T. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res 2000;60(20):5710-5713.
9. Antognelli C, Mearini L, Talesa VN, Giannantoni A, Mearini E. Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer. Prostate 2005;63(3):240-251.
10. Ntais C, Polycarpou A, Ioannidis JP. Association of the CYP17 gene polymorphism with the risk of prostate cancer: A metaanalysis. Cancer Epidemiol Biomarkers Prev 2003;12(2):120-126. (Pubitemid 36194001)
11. Lindstrom S, Adami HO, Balter KA, Xu J, Zheng SL, Stattin P, Gronberg H, Wiklund F. Inherited variation in hormoneregulating genes and prostate cancer survival. Clin Cancer Res 2007;13(17):5156-5161.
12. Setiawan VW, Schumacher FR, Haiman CA, Stram DO, Albanes D, Altshuler D, Berglund G, Buring J, Calle EE, Clavel-Chapelon F, Cox DG, Gaziano JM, Hankinson SE, Hayes RB, Henderson BE, Hirschhorn J, Hoover R, Hunter DJ, Kaaks R, Kolonel LN, Kraft P, Ma J, Le Marchand L, Linseisen J, Lund E, Navarro C, Overvad K, Palli D, Peeters PH, Pike MC, Riboli E, Stampfer MJ, Thun MJ, Travis R, Trichopoulos D, Yeager M, Ziegler RG, Spencer Feigelson H, Chanock SJ. CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev 2007;16(11):2237-2246. (Pubitemid 351196355)
13. Douglas JA, Zuhlke KA, Beebe-Dimmer J, Levin AM, Gruber SB, Wood DP, Cooney KA. Identifying susceptibility genes for prostate cancer-A family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-beta. Cancer Epidemiol Biomarkers Prev 2005;14(8):2035-2039. (Pubitemid 41161220)
14. Hamada A, Danesi R, Price DK, Sissung T, Chau C, Venzon D, Sparreboom A, Dahut WL, Figg WD. Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer. Urology 2007;70(2): 217-220.
15. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;26(28):4563-4571.
16. Stanford JL, Wicklund KG, McKnight B, Daling JR, Brawer MK. Vasectomy and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 1999;8(10):881-886.
17. Harrell F. Regression modeling strategies. New York: Springer; 2001.
18. Roach M III, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65(4):965-974.
19. Sawa H, Ohshima TA, Ukita H, Murakami H, Chiba Y, Kamada H, Hara M, Saito I. Alternatively spliced forms of cyclin D1 modulate entry into the cell cycle in an inverse manner. Oncogene 1998;16(13):1701-1712. (Pubitemid 28175051)
20. Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J. Alternate splicing produces a novel cyclin D1 transcript. Oncogene 1995;11(5):1005-1011.
21. Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P, Franks S, Williamson R. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 1994;3(10):1873-1876. (Pubitemid 24310487)
22. Kakinuma H, Tsuchiya N, Habuchi T, Ohyama C, Matsuura S, Wang L, Nakamura A, Kato T. Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: Implication for prostate cancer risk. Prostate Cancer Prostatic Dis 2004;7(4):333-337.
23. Nedelcheva Kristensen V, Haraldsen EK, Anderson KB, Lonning PE, Erikstein B, Karesen R, Gabrielsen OS, Borresen-Dale AL. CYP17 and breast cancer risk: The polymorphism in the 50 flanking area of the gene does not influence binding to Sp-1. Cancer Res 1999;59(12):2825-2828. (Pubitemid 29283117)
24. Severi G, Hayes VM, Tesoriero AA, Southey MC, Hoang HN, Padilla EJ, Morris HA, English DR, Sutherland RL, Boyle P, Hopper JL, Giles GG. The rs743572 common variant in the promoter of CYP17A1 is not associated with prostate cancer risk or circulating hormonal levels. BJU Int 2008;101(4):492-496.
25. Stigliano A, Gandini O, Cerquetti L, Gazzaniga P, Misiti S, Monti S, Gradilone A, Falasca P, Poggi M, Brunetti E, Agliano AM, Toscano V. Increased metastatic lymph node 64 and CYP17 expression are associated with high stage prostate cancer. J Endocrinol 2007;194(1):55-61.
26. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS. Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res 2008;68(11): 4447-4454.
27. Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM, Bremner WJ, Gleave ME, Nelson PS. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: Therapeutic implications for castration-resistant prostate cancer. Cancer Res 2007;67(10):5033-5041.
28. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008;68(15):6407-6415.
29. Gronberg H, Damber L, Jonson H, Damber JE. Prostate cancer mortality in northern Sweden, with special reference to tumor grade and patient age. Urology 1997;49(3):374-378.
30. Collette L. Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials. Eur Urol 2008; 53(1):6-9. (Pubitemid 350166730)
31. Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJ Jr, Lilja H, Scardino PT. Defining biochemical recurrence of prostate cancer after radical prostatectomy: A proposal for a standardized definition. J Clin Oncol 2006;24(24):3973-3978.